Found: 23
Select item for more details and to access through your institution.
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 9, p. 1629, doi. 10.1002/cncr.35170
- By:
- Publication type:
- Article
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 1, p. 53, doi. 10.1038/s41416-023-02487-5
- By:
- Publication type:
- Article
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
- Published in:
- Quality of Life Research, 2023, v. 32, n. 11, p. 3209, doi. 10.1007/s11136-023-03468-0
- By:
- Publication type:
- Article
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
- Published in:
- Prostate, 2022, v. 82, n. 11, p. 1107, doi. 10.1002/pros.24363
- By:
- Publication type:
- Article
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 10463, doi. 10.2147/CMAR.S208720
- By:
- Publication type:
- Article
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 5, p. 1052, doi. 10.1007/s10637-019-00731-5
- By:
- Publication type:
- Article
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 458, doi. 10.1007/s10637-018-0578-9
- By:
- Publication type:
- Article
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America.
- Published in:
- Prostate, 2015, v. 75, n. 8, p. 836, doi. 10.1002/pros.22965
- By:
- Publication type:
- Article
Expanding Androgen- and Androgen Receptor Signaling-Directed Therapies for Castration- Resistant Prostate Cancer.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 8, p. 693
- By:
- Publication type:
- Article
Expanding Androgen- and Androgen Receptor Signaling-Directed Therapies for Castration- Resistant Prostate Cancer.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Repetitively dosed docetaxel and <sup>153</sup>samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 17, p. 3186, doi. 10.1002/cncr.28103
- By:
- Publication type:
- Article
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 3, p. 537, doi. 10.1007/s00280-013-2224-8
- By:
- Publication type:
- Article
Phase I pharmacokinetic and biodistribution study with escalating doses of <sup>223</sup>Ra-dichloride in men with castration-resistant metastatic prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2013, v. 40, n. 9, p. 1384, doi. 10.1007/s00259-013-2427-6
- By:
- Publication type:
- Article
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Oncologist, 2013, v. 18, n. 2, p. 163, doi. 10.1634/theoncologist.2012-314
- By:
- Publication type:
- Article
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
- Published in:
- 2012
- By:
- Publication type:
- Report
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1004, doi. 10.1007/s10637-010-9447-x
- By:
- Publication type:
- Article
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 6, p. 1113, doi. 10.1007/s00280-010-1269-1
- By:
- Publication type:
- Article
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
- Published in:
- 2010
- By:
- Publication type:
- Report
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862).
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 23, p. 5541, doi. 10.1002/cncr.24597
- By:
- Publication type:
- Article